<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39383382</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1414-431X</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas</Title><ISOAbbreviation>Braz J Med Biol Res</ISOAbbreviation></Journal><ArticleTitle>Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial.</ArticleTitle><Pagination><StartPage>e13627</StartPage><MedlinePgn>e13627</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13627</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/1414-431X2024e13627</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0100-879X2024000100681</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has driven the search for alternative therapies, including convalescent plasma, historically used in infectious diseases. Despite results in other diseases, its effectiveness against COVID-19 remains uncertain with conflicting results in clinical trials. A pragmatic, single-center, prospective, and open randomized controlled trial was carried out in a hospital in Brazil, with the aim of evaluating the impact of convalescent plasma on the clinical improvement of patients hospitalized with COVID-19. The World Health Organization (WHO) ordinal scale was used to measure clinical improvement, focusing on the reduction in disease severity by up to 2 points, while antibody and C-reactive protein levels were monitored over time. After hospital admission, participants were randomized 1:1 to receive convalescent plasma and standard treatment or to be part of the control group with standard treatment. Follow-up was carried out on days 1, 3, 7, 14 and/or at discharge. From January 14 to April 4, 2022, 38 patients were included, but 3 were excluded due to protocol deviations, resulting in a total of 35 patients: 19 in the control group and 16 in the plasma group. There was no significant difference in clinical improvement between the convalescent plasma group and the control group, nor in secondary outcomes. The study had limitations due to the small number of patients and limited representation of COVID-19 cases. Broader investigations are needed to integrate therapies into medical protocols, both for COVID-19 and other diseases. Conducting randomized studies is challenging due to the complexity of medical conditions and the variety of treatments available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>T P</ForeName><Initials>TP</Initials><Identifier Source="ORCID">0000-0002-3465-7444</Identifier><AffiliationInfo><Affiliation>Diretoria Técnica e Qualidade, Maternidade e Cirurgia Nossa Senhora do Rocio-HR, Campo Largo, PR, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratório de Ciência e Tecnologia Aplicada è Saúde, Instituto Carlos Chagas, Fundação Oswaldo Cruz, Curitiba, PR, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5166-2897</Identifier><AffiliationInfo><Affiliation>Laboratório de Ciência e Tecnologia Aplicada è Saúde, Instituto Carlos Chagas, Fundação Oswaldo Cruz, Curitiba, PR, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>C M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6972-5830</Identifier><AffiliationInfo><Affiliation>Instituto de Pesquisa do Vale da Ciência, São Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Socca</LastName><ForeName>E</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6840-5114</Identifier><AffiliationInfo><Affiliation>Instituto de Pesquisa do Vale da Ciência, São Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itinose</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0001-8463-4793</Identifier><AffiliationInfo><Affiliation>Diretoria Técnica e Qualidade, Maternidade e Cirurgia Nossa Senhora do Rocio-HR, Campo Largo, PR, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>R</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0008-7816-4394</Identifier><AffiliationInfo><Affiliation>Diretoria Técnica e Qualidade, Maternidade e Cirurgia Nossa Senhora do Rocio-HR, Campo Largo, PR, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanes</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2929-6696</Identifier><AffiliationInfo><Affiliation>Laboratório de Ciência e Tecnologia Aplicada è Saúde, Instituto Carlos Chagas, Fundação Oswaldo Cruz, Curitiba, PR, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05077930</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D065007">Pragmatic Clinical Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Med Biol Res</MedlineTA><NlmUniqueID>8112917</NlmUniqueID><ISSNLinking>0100-879X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="Y">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>22</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>15</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39383382</ArticleId><ArticleId IdType="pmc">PMC11463911</ArticleId><ArticleId IdType="doi">10.1590/1414-431X2024e13627</ArticleId><ArticleId IdType="pii">S0100-879X2024000100681</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO (World Health Organization)  Coronavirus disease (COVID-19) pandemic.  [Acessed January 26, 2023]. https://www.who.int/europe/emergencies/situations/covid-19</Citation></Reference><Reference><Citation>Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456. doi: 10.1093/cid/ciq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq106</ArticleId><ArticleId IdType="pmc">PMC7531589</ArticleId><ArticleId IdType="pubmed">21248066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–473. doi: 10.1378/chest.12-2907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.12-2907</ArticleId><ArticleId IdType="pubmed">23450336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi: 10.1093/infdis/jiu396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu396</ArticleId><ArticleId IdType="pmc">PMC4264590</ArticleId><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of immune escape variants from antibody-based therapeutics against COVID-19: a systematic review. Int J Mol Sci. 2021;23:29. doi: 10.3390/ijms23010029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010029</ArticleId><ArticleId IdType="pmc">PMC8744556</ArticleId><ArticleId IdType="pubmed">35008446</ArticleId></ArticleIdList></Reference><Reference><Citation>V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H, Liu B, Wang X, Zhang L. The humoral response and antibodies against SARS- CoV-2 infection. Nat Immunol. 2022;23:1008–1020. doi: 10.1038/s41590-022-01248-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01248-5</ArticleId><ArticleId IdType="pubmed">35761083</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22:e311–e326. doi: 10.1016/S1473-3099(22)00311-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00311-5</ArticleId><ArticleId IdType="pmc">PMC9255948</ArticleId><ArticleId IdType="pubmed">35803289</ArticleId></ArticleIdList></Reference><Reference><Citation>Moubarak M, Kasozi KI, Hetta HF, Shaheen HM, Rauf A, Al-Kuraishy HM, et al. The rise of SARS-CoV-2 variants and the role of convalescent plasma therapy for management of infections. Life (Basel) 2021;11:734. doi: 10.3390/life11080734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11080734</ArticleId><ArticleId IdType="pmc">PMC8399171</ArticleId><ArticleId IdType="pubmed">34440478</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Casadevall A. Convalescent plasma in outpatients with COVID-19. Lancet Respir Med. 2022;10:226–228. doi: 10.1016/S2213-2600(22)00050-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00050-9</ArticleId><ArticleId IdType="pmc">PMC8828368</ArticleId><ArticleId IdType="pubmed">35150608</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Priyanka, Parmar M, Angural S, Choudhary OP. Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks. Int J Surg. 2022;97:106204. doi: 10.1016/j.ijsu.2021.106204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2021.106204</ArticleId><ArticleId IdType="pmc">PMC8717699</ArticleId><ArticleId IdType="pubmed">34974199</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–2059. doi: 10.1016/S0140-6736(21)00897-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00897-7</ArticleId><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, Marc GP, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610–618. doi: 10.1056/NEJMoa2033700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clinl Microbiol Rev. 2022;35:e0020021. doi: 10.1128/cmr.00200-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.00200-21</ArticleId><ArticleId IdType="pmc">PMC9491201</ArticleId><ArticleId IdType="pubmed">35262370</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconato M, Abela IA, Hauser A, Schwarzmuller M, Katzensteiner R, Braun DL, et al. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. J Clin Invest. 2022;132:e158190. doi: 10.1172/JCI158190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI158190</ArticleId><ArticleId IdType="pmc">PMC9197521</ArticleId><ArticleId IdType="pubmed">35482408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz JR, Rudd KE, Clark DV, Jacob ST, West TE. Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. Critl Care Med. 2013;41:1345–1352. doi: 10.1097/CCM.0b013e3182771386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182771386</ArticleId><ArticleId IdType="pubmed">23399939</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Zhou J, Huang Y, Liu X, Xu Y, Chen S, et al. Efficacy of convalescent plasma for the treatment of severe influenza. Crit Care. 2020;24:469. doi: 10.1186/s13054-020-03189-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03189-7</ArticleId><ArticleId IdType="pmc">PMC7388480</ArticleId><ArticleId IdType="pubmed">32727526</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Pirofski LA, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio. 2021;12:e03372–e03420. doi: 10.1128/mBio.03372-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.03372-20</ArticleId><ArticleId IdType="pmc">PMC8092292</ArticleId><ArticleId IdType="pubmed">33653885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Zhang J, Wang P, Zhang Z. The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. iScience. 2022;25:105044. doi: 10.1016/j.isci.2022.105044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105044</ArticleId><ArticleId IdType="pmc">PMC9436868</ArticleId><ArticleId IdType="pubmed">36068846</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, McConnell S, Casadevall A. The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. Drug Resist Updat. 2022;65:100882. doi: 10.1016/j.drup.2022.100882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2022.100882</ArticleId><ArticleId IdType="pmc">PMC9528072</ArticleId><ArticleId IdType="pubmed">36260961</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor- binding domain by structure-guided high-resolution serology. Cell. 2020;183:1024–1042.e21. doi: 10.1016/j.cell.2020.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, Consortium C-GU, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21:112–124. doi: 10.1038/s41579-022-00809-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00809-7</ArticleId><ArticleId IdType="pmc">PMC9616429</ArticleId><ArticleId IdType="pubmed">36307535</ArticleId></ArticleIdList></Reference><Reference><Citation>FIOCRUZ  Relatório da Rede Genômica Fiocruz referente ao período de 6 a 16 de junho de 2022.  [Acessed January 5, 2023]. https://portal.fiocruz.br/documento/relatorio-da-rede-genomica-fiocruz</Citation></Reference><Reference><Citation>Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022 Feb;185(3):467–84 e15. doi: 10.1016/j.cell.2021.12.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.046</ArticleId><ArticleId IdType="pmc">PMC8723827</ArticleId><ArticleId IdType="pubmed">35081335</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  Emergency use authorization (eua) of covid-19 Convalescent plasma for treatment of Coronavirus Disease 2019 (COVID-19)  [Acessed January 26, 2023]. https://www.fda.gov/media/141478/download</Citation></Reference><Reference><Citation>NIH  COVID-19 Convalescent Plasma.  [Acessed January 26, 2023]. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/</Citation></Reference><Reference><Citation>Bayati M, Noroozi R, Ghanbari-Jahromi M, Jalali FS. Inequality in the distribution of Covid-19 vaccine: a systematic review. Int J Equity Health. 2022;30(21):122. doi: 10.1186/s12939-022-01729-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12939-022-01729-x</ArticleId><ArticleId IdType="pmc">PMC9425802</ArticleId><ArticleId IdType="pubmed">36042485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent Plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021;27:2012–2024. doi: 10.1038/s41591-021-01488-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01488-2</ArticleId><ArticleId IdType="pmc">PMC8604729</ArticleId><ArticleId IdType="pubmed">34504336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li J, Zhang L, Sun H-X, Zhang Z, Xu J, et al. Plasma cell-free RNA characteristics in COVID-19 patients. Genome Res. 2022;32:228–241. doi: 10.1101/gr.276175.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.276175.121</ArticleId><ArticleId IdType="pmc">PMC8805721</ArticleId><ArticleId IdType="pubmed">35064006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>